The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] GSK announces availability of Authorized Generic Albuterol Sulfate Inhaler for treatment or prevention of bronchospasm Effective, January 15, 2019, GSK announced the availability of an authorized generic (AG) of Ventolin HFA (albuterol sulfate) inhalation aerosol. The AG will be manufactured by GSK and distributed by Prasco LLC. The...
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ProAir ® Digihaler™ (albuterol sulfate 117 mcg) inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. Learn more.
Earlier this year, AAFA surveyed members of our community about clinical trials for asthma and allergies. Most people said they would be willing to consider clinical trials. But only 9% of the people said they had been invited to participate in one! Learn what else we found about participation in clinical trials.
Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that Fractional Exhaled Nitric Oxide (FeNO) monitoring is recommended in the latest Global Initiative for Asthma (GINA) guide, “Difficult-to-Treat & Severe Asthma in Adolescent and Adult Patients – Diagnosis and Management.”
If you’ve suffered with severe atopic dermatitis (eczema) for a long time and have tried what you think is every available option for relief, you may want to consider allergy shots. A medically-challenging case being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting found that allergy shots provided significant benefits to the eczema symptoms suffered by a 48-year-old man.
It’s well established that secondhand smoke from cigarettes is a risk to anyone who suffers from asthma. New research being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting shows it’s possible for both children and adults with uncontrolled asthma to find their symptoms worsening due to cannabis allergy and exposure to marijuana smoke.
Asthma is a complex disease, and it can be a challenge to keep up with your child’s medications and treatments. New research being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting shows children of caregivers with poor asthma knowledge were four times more likely to have a prolonged hospital stay. A “prolonged” stay was defined as more than two days.
If the thought of sucking your baby’s pacifier to clean it and then popping it in your baby’s mouth grosses you out, think again. New research being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting suggests a link between parental sucking on a pacifier and a lower allergic response among young children.
Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions For Immediate Release November 7, 2018 Contact Consumers Recall Department email@example.com Announcement Kadesh, Inc. of Garden Grove, CA is voluntarily recalling all lots of Puriton Eye Relief Drops, 0.5 oz. (15ml) bottle, UPC 7 36972 1679 0, to the consumer level. During a recent FDA inspection, investigators observed that ophthalmic drugs, which are required to be...
FDA is alerting patients, caregivers and health care professionals that the labels attached to some EpiPen 0.3mg and EpiPen Jr 0.15mg auto-injectors, and the authorized generic versions, may block access to the auto-injector and prevent the ability to easily access the product.
Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype and oral corticosteroid-dependent asthma, regardless of phenotype.
The Asthma and Allergy Foundation of America (AAFA) led a research study called Atopic Dermatitis in America . The purpose of this study is to shed light on the number of adults who deal with this frustrating skin condition. This week, AAFA has released early findings from the report. One surprising find from the study was the number of adults with AD who say it is moderate to severe. As many as 40% of the people surveyed said they had moderate-to-severe AD. Through this study, we hope to...
Ragweed and other fall allergens are found throughout the U.S., but some areas feel the effects more than others. The Asthma and Allergy Foundation of America (AAFA) has released the 2018 Fall Allergy Capitals™ report.
AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.